SCHEMBL19355451

SCHEMBL19355451

CNC(=O)c1ccc(CCNc2cc(-c3ccc(NC(C)COC)nc3)ncn2)c(OC)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR3 P49019 2/20 0.45
PDE10A Q9Y233 1/20 0.43
CYP1A2 P05177 8/20 0.41
CYP3A4 P08684 8/20 0.41
CLK4 Q9HAZ1 8/20 0.41
CYP2D6 P10635 7/20 0.41
USP2 O75604 5/20 0.41
CYP2C19 P33261 6/20 0.41
ROCK2 O75116 1/20 0.37
ROCK1 Q13464 1/20 0.37
ALDH1A1 P00352 4/20 0.36
TSHR P16473 3/20 0.36
HSD17B10 Q99714 3/20 0.36
LMNA P02545 1/20 0.36
PIK3CA P42336 1/20 0.36
ABL1 P00519 3/20 0.36
BCR P11274 3/20 0.36
ALOX15 P16050 2/20 0.36
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19355452 1.00 HCAR3 (0.45) HCAR3PDE10ACYP1A2CYP3A4CLK4
SCHEMBL19355388 0.90 CYP1A2 (0.44) HCAR3CYP1A2CYP3A4CLK4CYP2D6
SCHEMBL15356521 0.88 CYP1A2 (0.47) CYP1A2CYP3A4CLK4CYP2D6USP2
SCHEMBL19355397 0.87 CYP1A2 (0.44) HCAR3CYP1A2CYP3A4CLK4CYP2D6
SCHEMBL15343009 0.85 HCAR3 (0.45) HCAR3PDE10ACYP1A2CYP3A4CLK4
SCHEMBL15343002 0.85 HCAR3 (0.45) HCAR3PDE10ACYP1A2CYP3A4CLK4
SCHEMBL19355068 0.85 CYP1A2 (0.42) CYP1A2CYP3A4CLK4CYP2D6USP2
SCHEMBL19905232 0.85 CLK4 (0.46) CYP1A2CYP3A4CLK4CYP2D6USP2
SCHEMBL19355069 0.84 CYP1A2 (0.42) HCAR3CYP1A2CYP3A4CLK4CYP2D6
SCHEMBL16660255 0.83 CYP1A2 (0.49) CYP1A2CYP3A4CLK4CYP2D6USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180193341-A1 DNA-PK INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED 2018-07-12 US disclosed
EP-3057959-B1 DNA-PK INHIBITORS VERTEX PHARMA (US) 2018-02-28 EP disclosed
US-20170258789-A1 DNA-PK INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2017-09-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170258789-A1 DNA-PK INHIBITORS POLK, DTYMK, DCK HCAR3 4144/4885PDE10A 1163/4885CYP1A2 2215/4885
US-20180193341-A1 DNA-PK INHIBITORS POLK, DTYMK, DCK HCAR3 4144/4885PDE10A 1163/4885CYP1A2 2215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.